TOKYO, Oct 3 – Sato Pharmaceutical Co., Ltd., Eisai Co., Ltd., and Seren Pharmaceuticals Inc. announced today that Sato Pharma and Eisai will co-promote a new triazole class oral antifungal agent (development code: BFE1224, “the agent”) containing the active ingredient fosravuconazole L-lysine ethanolate (“fosravuconazole”) in Japan, based on an agreement between the three companies.
The agent is currently under regulatory review for the treatment of onychomycosis. After receiving regulatory approval, Sato Pharma will begin distributing the agent, and Sato Pharma and Eisai will jointly provide information on its proper use. Fosravuconazole is a new oral antifungal component developed by Eisai. In 2010, Eisai concluded a license agreement with Seren Pharma (formerly known as “Brain Factory Co., Ltd.”), granting them exclusive rights to develop, commercialize, and sublicense the agent in Japan.
In 2014, Seren Pharma concluded an agreement with Sato Pharma, granting them the development and commercialization rights, and both companies continued to develop the agent for treating onychomycosis. In January 2017, Sato Pharma applied for marketing authorization for the agent. Sato Pharma, Eisai, and Serena Pharma will cooperate to maximize the value of fosravuconazole in order to fulfil the unmet medical needs of patients with fungal diseases.